Clinical Policy Title: Indications for Mohs micrographic surgery

Size: px
Start display at page:

Download "Clinical Policy Title: Indications for Mohs micrographic surgery"

Transcription

1 Clinical Policy Title: Indications for Mohs micrographic surgery Clinical Policy Number: CCP.1056 Effective Date: March 1, 2014 Initial Review Date: September 18, 2013 Most Recent Review Date: October 2, 2018 Next Review Date: October 2019 Related policies: Policy contains: Basal cell carcinoma. Malignant melanoma. Mohs micrographic surgery. Squamous cell carcinoma. None. ABOUT THIS POLICY: Select Health of South Carolina has developed clinical policies to assist with making coverage determinations. Select Health of South Carolina s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Select Health of South Carolina when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Select Health of South Carolina ss clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Select Health of South Carolina s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Select Health of South Carolina will update its clinical policies as necessary. Select Health of South Carolina s clinical policies are not guarantees of payment. Coverage policy Select Health of South Carolina considers Mohs micrographic surgery to be clinically proven and, therefore, medically necessary when any of the following criteria are met: 1. When performed in anatomic areas with high risk of recurrence of cancer (especially around nose, mouth, eyes, and central third of face), external ear and tragus, temple, scalp, mucosal lesions, and nail bed and periungual areas; or 2. Cancer located in areas where tissue preservation is important for maximum functional and cosmetic result, including the face, ears, hands, feet, and genitalia; or 3. Recurrent or incompletely excised malignant lesions, regardless of anatomic region; or 4. Tumor occurring in previously irradiated skin areas in any anatomic region; or 5. For exceptionally large (>2 centimeters in diameter) lesions in any anatomic region; or 6. Cancer displaying aggressive behavior (see Policy Guidelines below) or rapid growth in any anatomic region; or 7. When the cancer has ill-defined borders; or 8. Malignant lesions in immunosuppressed patients; or 1

2 9. The tumor is associated with high risk of metastasis (e.g., Bowen s disease, discoid lupus erythematosus, and lichen sclerosis) (Ad Hoc Task Force, 2012). Limitations: None. Alternative covered services: Each case must be individualized when considering other treatment options. Depending on the type, extent, size, and location of nonmelanoma skin cancers, other treatment options include: Electrodesiccation and curettage. Excisional surgery. Radiation therapy. Topical creams. Chemotherapy. Cryosurgery. Photodynamic therapy. Laser surgery. Background In the U.S., 5.4 million new cases of non-melanoma skin cancers in 3.3 million persons were diagnosed in 2012 (Skin Cancer Foundation, 2018), along with 91,270 cases of melanoma in 2018 (Noone, 2018). The number of non-melanoma skin cancers has increased 77 percent from 1994 to 2014 (Skin Cancer Foundation, 2018). The number of Mohs surgeries performed on tumors each year in the U.S. is at least 876,000 (Asgari, 2012). Mohs micrographic surgery use has increased 400 percent from 1995 to 2009, and one-fourth of skin cancers are treated using this procedure (Ad Hoc Task Force, 2012). Mohs micrographic surgery is named after the physician who developed the original technique. Frederic Mohs was a practicing physician in Wisconsin the 1930s who discovered a new way to treat skin cancer tumors. Mohs micrographic surgery is a precise tissue-sparing surgical technique to remove and treat selected malignant neoplasms of the skin. Mohs micrographic surgery is perhaps the most effective treatment for basal cell carcinoma and squamous cell carcinoma, and improvements in identifying cancerous cells have made the technique more effective in treating melanoma (Skin Cancer Foundation, 2017). The majority of simple skin cancers can be managed by excision or destruction techniques. The medical record should clearly show that Mohs micrographic surgery was chosen because of the complexity (e.g., poorly defined clinical borders, possible deep invasion, and prior irradiation), size, or location (e.g., 2

3 maximum conservation of tumor-free tissue is important). Mohs micrographic surgery is usually an outpatient procedure done under local anesthesia (with or without sedation). Mohs differs from other types of skin cancer surgery, as it removes the cancer by layers. Margins are examined of each layer, until the tissue is completely cancer free ( clear margins ), minimizing the amount of healthy tissue that has been removed, and removing far more cancerous tissue than in traditional excisions. Because the Mohs surgeon has received special training in both surgery and pathology, the ability to remove only the cancerous tissue is enhanced (American College of Mohs Surgery, 2017). The procedure is performed on an ambulatory basis. After a local anesthetic is administered, the surgeon scrapes the portion of the skin with the most evident cancer. Downward and cross- incisions are made, and the surgeon draws a map of the area and excised tissue. While the patient waits, specimens are frozen, cut, transferred to slides and examined, a process that often lasts 30 to 60 minutes. If any tumor remains, more anesthesia is given, and the process is repeated (only removing tissue from the cancerous area), and new slides are prepared and analyzed. While the surgery can be completed in just one such stage, it typically takes two or three stages (Harvard Medical School, 2006). If stitches are made, they typically are removed in less than one week. If the surgeon decides to allow the excision area to close on its own, it typically takes about a month to heal. Skin grafts and skin flaps may be used instead of stitches (Harvard Medical School, 2006). A complications registry has been developed by the American College of Mohs Surgery. Four major and one minor types of complications are included: death, bleeding requiring additional intervention, functional loss attributable to surgery, hospitalization for an operative complication, and surgical site infection (Council, 2016). Searches Select Health of South Carolina searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services. We conducted searches on August 9, Search terms were: basal cell carcinoma, squamous cell carcinoma and Mohs micrographic. We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use 3

4 predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings Guidelines have been developed by the American Academy of Dermatology that recommend when Mohs micrographic surgery is or is not appropriate (Ad Hoc Task Force, 2012). The guidelines present 270 scenarios based on patient condition; of these, 200 (74.1 percent) are considered appropriate, 24 (8.9 percent) uncertain, and 46 (17.0 percent) inappropriate (see below): Scenarios Condition Appropriate Uncertain Inappropriate 69 Basal cell carcinoma Squamous cell carcinoma Lentigo maligna + melanoma Rare cutaneous malignancies TOTAL Other guidelines, such as those from the United Kingdom and Scotland, recommend that Mohs micrographic surgery be considered for squamous cell carcinoma (British Association of Dermatologists, 2014; Scottish Intercollegiate Guidelines Network, 2014). A 2016 guideline recommended Mohs for high-risk basal cell carcinoma, aggressive recurrent squamout cell cardinoma, cancers of the ear, lips, and middle of the face, and dermatofibrosarcoma protuberans (Cernea, 2016). A total of 195,768 melanomas were diagnosed from 2003 through 2009 from 17 state and metropolitan cancer registries. Utilization of Mohs micrographic surgery for invasive melanoma and melanoma in situ increased by 60 percent from 2003 to Of all lesions treated by surgical excision in this time period, 3.5 percent (6872) were excised by Mohs micrographic surgery. Use of Mohs micrographic surgery for melanoma appears to be increasing (Viola, 2015). Little data exists comparing outcomes of Mohs micrographic surgery to other surgical procedures for certain cancers. For example, a Cochrane review of persons treated for basal cell carcinoma, either with Mohs micrographic surgery or surgical excision, was unable to locate any randomized controlled trials that met criteria for such a comparison (Narayanan, 2014). A systematic review of 40 studies, 29 of them randomized controlled trials, revealed that the gold standard for treating basal cell carcinoma was Mohs micrographic surgery (Clark, 2014). Most efficacy studies of Mohs micrographic surgery focused on recurrence rates, and these have been favorable to Mohs micrographic surgery. One review that compared five types of treatment for basal 4

5 cell carcinoma observed five-year recurrence rates for Mohs micrographic surgery (one percent) are well below those for surgical excision (10.1), electrodessication and curettage (7.7), radiation therapy (8.7) and cryotherapy (7.5) (Tierney, 2009). Another study of 166 patients with basal cell carcinoma, half treated with Mohs micrographic surgery and half with standard surgery, observed two and 10 persons with recurrence within five years, a significant difference at P =.015 (Mosterd, 2008). A systematic review of 21 studies, each with at least 30 subjects, addressed recurrences, cure, complications, cosmesis, and quality of life. The authors recommended Mohs for all recurrent basal cell carcinomas of the face and primary cases >1 cm, have aggressive histology, or are located on the H zone of the face. Recommendations were not made for skin cancers other than basal cell (Murray, 2018). A comparison of 408 patients with primary basal cell carcinoma and another 204 with a recurrence that underwent either Mohs micrographic surgery or standard surgery showed a lower recurrence rate for Mohs micrographic surgery. The 10-year recurrence rates were 4.4 percent after Mohs micrographic surgery and 12.2 percent after surgery, not significant at P =.10. Ten-year rates for recurrent cases were 3.9 percent for Mohs micrographic surgery and 13.5 percent for surgery, significant at P =0.023). A substantial proportion of recurrences occurred after more than five years post-treatment (van Loo, 2014). A comparison of Mohs micrographic surgery and wide local excision for treating melanoma in situ (n=662) found similar five-year survival rates (92 percent for Mohs micrographic surgery, 94 percent for wide local excision, P =.28). Persons with Mohs micrographic surgery had lower total and five-year recurrence rates (1.8 versus 5.7 percent, and 1.1 versus 4.1 percent). The differences were of borderline significance at P =.07 (Nosrati, 2017). A systematic review of 118 observational studies of treatments for squamous cell carcinoma analyzed local recurrence rates. The rate after Mohs micrographic surgery (10 studies, 3.0 percent), was lower than for standard surgical excision (12 studies, 5.4 percent), external radiography (6.4 percent, seven studies), and photodynamic therapy (eight studies, 26.4 percent). The lower rate for Mohs micrographic surgery differed significantly only with photodynamic therapy. The five-year cure rate for Mohs micrographic surgery was 97.4 percent (a range of 95.7 to 98.8 percent), with most studies tracked for five years after surgery (Lansbury, 2013). A comparison of 23 non-randomized studies of patients treated by Mohs micrographic surgery or wide local excision for dermatofibrosarcoma protuberans showed a lower recurrence rate for Mohs micrographic surgery (1.11 percent) versus after wide local excision (6.32 percent); mean follow-up was 68 months (Foroozan, 2012). A review of five meta-analyses and 38 studies showed, despite a lack of strong data, that Mohs micrographic surgery had lower recurrence rates than other treatments for dermatofibrosarcoma protuberans (Pallure, 2013). A review of 20,821 cases at 23 medical centers who underwent Mohs micrographic surgery showed that 149, or 0.72 percent, had an adverse event. Almost all of these were infections, dehiscence/necrosis, or bleeding/hematoma (Alam, 2013). 5

6 A randomized controlled trial of 30 patients with basal cell carcinoma compared the size of the excised area for Mohs micrographic surgery and standard surgery. Tumors in subjects in the Mohs micrographic surgery group were initially excised with 2-mm margins (and the same size margins for any subsequent excision), half of the size for standard surgery. The median total area removed in the Mohs micrographic surgery group was significantly less than the standard surgery group versus mm 2, P <.001) (Muller, 2009). A recent review of 882 MMS cases suggested that the 17 percent of melanoma in situ cases that require margins >5 mm can be treated effectively using Mohs micrographic surgery (Stigall, 2016). Of 62 patients with melanomas treated with Mohs micrographic surgery, local recurrence-free survival was 91.8 percent at five years and 82.6 percent at 10 years (Terushkin, 2016). One literature review not only determined that Mohs micrographic surgery had superior outcomes (cure rates while optimizing tissue preservation) for high-risk cases of basal cell carcinoma, but also was the most cost-effective of any studied option (Kauvar, 2015). This conclusion was consistent with an earlier study, which found Mohs to be efficacious, and equaled the cost of excision with permanent sections, was 12 percent less costly than office-based excision with frozen sections, and 27 percent less costly than excision with frozen sections in an ambulatory surgical (Tierney, 2009). Policy updates: A total of four guidelines/other and three peer-reviewed references were added to this policy in August Summary of clinical evidence: Citation Alam (2013) Adverse events after Mohs micrographic surgery Lansbury (2013) Recurrence and survival rates after Mohs micrographic surgery versus standard surgery Muller (2009) Content, Methods, Recommendations Key points: Study of adverse events of 20,821 patients who underwent Mohs micrographic surgery. A total of 149 patients (0.72 percent (%)) had an adverse event. Almost all adverse events were infections, dehiscence/necroses, and bleeding/hematomas. Key points: Systematic review of 118 studies of patients treated for squamous cell carcinoma 12 studies (n=1529) included Mohs micrographic surgery patients. Average five year survival is 97.4%. Recurrence was 3.0% for Mohs micrographic surgery, lower than 5.4% for standard surgical excision, 6.4% for external radiotherapy, and 26.4% for photodynamic therapy. Key points: Comparison of amount of area excised, Mohs Randomized Controlled Trial of 30 patients with basal cell carcinoma. 6

7 Citation micrographic surgery versus standard surgery Mosterd (2008) Content, Methods, Recommendations Patients with Mohs micrographic surgery excised using 2 millimeter margins, surgical patients with 4 millimeters. Median total area removed was significantly lower for Mohs micrographic surgery (116.6 versus mm, P <.001. Key points: Comparison of recurrence in Mohs micrographic surgery patients versus surgical excision patients A prospective randomized controlled trial of basal cell carcinoma cases, 408 primary and 204 recurrent, treated with Mohs micrographic surgery or surgical excision. After five years, primary Mohs micrographic surgery patients had 2.5% recurrence versus 4.1% for surgical patients, not significant at P =.397. After five years, recurrent Mohs micrographic surgery patients had 2.4% recurrence versus 12.1% for surgical patients, significant at P =.015. References Professional society guidelines/other: Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4): American College of Mohs Surgery. Overview of Mohs Micrographic Surgery. Milwaukee WI: American College of Mohs Surgery, last updated March 2, Accessed August 9, British Association of Dermatologists. British Association of Dermatologists guideline for the management of squamous cell carcinoma in situ (Bowen s Disease). Revised February Accessed August 9, Cernea SS, Gontijo G, Pimental ER de A, et al. Indication guidelines for Mohs micrographic surgery in skin tumors. An Bras Dermatol. 2016; 91(5): Doi: /abd Harvard Medical School, Harvard Health Publications. What is Mohs Micrographic Surgery? Cambridge MA: Harvard University, May, Accessed August 9, Noone AM, Howlader N, Krapcho M, et al (eds). SEER Cancer Statistics Review, , Bethesda MD: National Cancer Institute, April

8 Accessed August 9, Scottish Intercollegiate Guidelines Network (SIGN). Management of primary cutaneous squamous cell carcinoma: a national clinical guideline. Last revised June, Accessed August 9, Skin Cancer Foundation. Mohs Micrographic Surgery: An Overview. New York: Skin Cancer Foundation, Accessed August 9, Skin Cancer Foundation. Skin Cancer Facts and Statistics. New York: Skin Cancer Foundation, last updated May 3, Accessed August 9, Peer-reviewed references: Alam M, Ibrahim O, Nodzenski M, et al. Adverse events associated with mohs micrographic surgery: multicenter prospective cohort study of 20,821 cases at 23 centers. JAMA Dermatol. 2013;149(12): Doi: /jamadermatol Asgari MM, Olson J, Alam M. Needs assessment for Mohs micrographic surgery. Dermatol Clin. 2012; 30(1): Doi: /j.det Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3): Doi: /s z. Council ML, Alam M, Gloster HM Jr, et al. Identifying and defining complications of dermatologic surgery to be tracked in the American College of Mohs Surgery (ACMS) Registry. J Am Acad Dermatol. 2016;74(4): Doi: /j.jaad Foroozan M, Sei JF, Amini M, Beauchet A, Saiag P. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9): Doi: /archdermatol Kauvar AN, Cronin T Jr., Roenigk R. Hruza G, Bennett R, American Society for Dermatologic Surgery. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(5): Doi: /DSS Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. Doi: /bmj.f6153.Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision 8

9 versus Mohs micrographic surgery for primary and recurrent basal-cell carcinoma of the face: A prospective randomized controlled trial with 5-Years' follow-up. Lancet Oncol. 2008; 9(12): Doi: /S (08) Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg. 2009; 35(9): Doi: /j x. Murray C, Sivajohanathan, Hanna TP. Patient indications for Mohs micrographic surgery: A systematic review. J Cutan Med Surg Jul 1: Doi: / Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev Dec 12;(12):CD Doi: / CD pub4. Nosrati A, Berliner JG, Goel S, et al. Outcomes of melanoma in situ treated with Mohs micrographic surgery compared with wide local excision. JAMA Dermatol. 2017;153(5): Pallure V, Dupin N, Guillot B. Association for Recommendations in Dermatology. Surgical treatment of Darier-Ferrand dermatofibrosarcoma: a systematic review. Dermatol Surg. 2013;39(10): Doi: /dsu Stigall LE, Brodland DG, Zitelli JA. The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities. J Am Acad Dermatol. 2016;75(5): Doi: /j.jaad Terushkin V, Brodland DG, Sharon DJ, Zitelli JA. Digit-sparing Mohs surgery for melanoma Dermatol Surg. 2016; 42(1): Doi: /DSS Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol. 2009;8(10): Van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17): Doi: /j.ejca Veronese F, Farinelli P, Zavattaro E, et al. Basal cell carcinoma of the head region: therapeutical results of 350 lesions treated with Mohs micrographic surgery. J Eur Acad Dermatol Venereol ;26(7): Viola KV, Rezzadeh KS, Gonsalves L, et al. National utilization patterns of Mohs micrographic surgery for invasive melanoma and melanoma in situ..j Am Acad Dermatol. 2015; 72(6): Doi: 9

10 /j.jaad Centers for Medicare & Medicaid Services National Coverage Determinations: No National Coverage Determinations identified as of the writing of this policy. Local Coverage Determinations: Mohs Micrographic Surgery (L33436, L33689, L33979, L34195, L34233, L34961, L35494, L35702, L35704) Effective October 1, Accessed August 9, Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comment Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s), head, neck, hand, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerve or vessels; first stage, up to 5 tissue blocks Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s), head, neck, hand, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerve or vessels; each additional stage after first stage, up to 5 tissue blocks Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) of the trunk, arms or legs; first stage, up to 5 tissue blocks Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) of the trunk, arms or legs; each additional stage after the first stage, up to 5 tissue blocks Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s), each additional block after the first 5 tissue blocks, any stage 10

11 ICD-10 Code Description Comment C00.0 Malignant neoplasm of external upper lip C00.1 Malignant neoplasm of external lower lip C00.3 Malignant neoplasm of upper lip, inner aspect C00.4 Malignant neoplasm of lower lip, inner aspect C00.5 Malignant neoplasm of lip, unspecified, inner aspect C00.8 Malignant neoplasm of overlapping sites of lip C00.2 Malignant neoplasm of external lip, unspecified C00.9 Malignant neoplasm of lip, unspecified C44.01 Basal cell carcinoma of skin of lip C44.02 Squamous cell carcinoma of skin of lip C44.09 Other specified malignant neoplasm of skin of lip C Basal cell carcinoma of skin of unspecified eyelid, including canthus C Basal cell carcinoma of skin of right eyelid, including canthus C Basal cell carcinoma of skin of left eyelid, including canthus C Squamous cell carcinoma of skin of unspecified eyelid, including canthus C Squamous cell carcinoma of skin of right eyelid, including canthus C Squamous cell carcinoma of skin of left eyelid, including canthus C Other specified malignant neoplasm of skin of unspecified eyelid, including canthus C Other specified malignant neoplasm of skin of right eyelid, including canthus C Other specified malignant neoplasm of skin of left eyelid, including canthus C Basal cell carcinoma of skin of unspecified ear and external auricular canal C Basal cell carcinoma of skin of right ear and external auricular canal C Basal cell carcinoma of skin of left ear and external auricular canal C Squamous cell carcinoma of skin of unspecified ear and external auricular canal C Squamous cell carcinoma of skin of right ear and external auricular canal C Squamous cell carcinoma of skin of left ear and external auricular canal C Other specified malignant neoplasm of skin of unspecified ear and external auricular canal C Other specified malignant neoplasm of skin of right ear and external auricular canal C Other specified malignant neoplasm of skin of left ear and external auricular canal C Basal cell carcinoma of skin of unspecified parts of face C Basal cell carcinoma of skin of nose C Basal cell carcinoma of skin of other parts of face C Squamous cell carcinoma of skin of unspecified parts of face C Squamous cell carcinoma of skin of nose C Squamous cell carcinoma of skin of other parts of face C Other specified malignant neoplasm of skin of unspecified parts of face C Other specified malignant neoplasm of skin of nose C Other specified malignant neoplasm of skin of other parts of face C44.41 Basal cell carcinoma of skin of scalp and neck C44.42 Squamous cell carcinoma of skin of scalp and neck 11

12 ICD-10 Code Description Comment C44.49 Other specified malignant neoplasm of skin of scalp and neck C Basal cell carcinoma of anal skin C Basal cell carcinoma of skin of breast C Basal cell carcinoma of skin of other part of trunk C Squamous cell carcinoma of anal skin C Squamous cell carcinoma of skin of breast C Squamous cell carcinoma of skin of other part of trunk C Other specified malignant neoplasm of anal skin C Other specified malignant neoplasm of skin of breast C Other specified malignant neoplasm of skin of other part of trunk C Basal cell carcinoma of skin of unspecified upper limb, including shoulder C Basal cell carcinoma of skin of right upper limb, including shoulder C Basal cell carcinoma of skin of left upper limb, including shoulder C Squamous cell carcinoma of skin of unspecified upper limb, including shoulder C Squamous cell carcinoma of skin of right upper limb, including shoulder C Squamous cell carcinoma of skin of left upper limb, including shoulder C Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder C Other specified malignant neoplasm of skin of right upper limb, including shoulder C Other specified malignant neoplasm of skin of left upper limb, including shoulder C Basal cell carcinoma of skin of unspecified lower limb, including hip C Basal cell carcinoma of skin of right lower limb, including hip C Basal cell carcinoma of skin of left lower limb, including hip C Squamous cell carcinoma of skin of unspecified lower limb, including hip C Squamous cell carcinoma of skin of right lower limb, including hip C Squamous cell carcinoma of skin of left lower limb, including hip C Other specified malignant neoplasm of skin of unspecified lower limb, including hip C Other specified malignant neoplasm of skin of right lower limb, including hip C Other specified malignant neoplasm of skin of left lower limb, including hip C44.81 Basal cell carcinoma of overlapping sites of skin C44.82 Squamous cell carcinoma of overlapping sites of skin C44.89 Other specified malignant neoplasm of overlapping sites of skin HCPCS Level II Code N/A Description Comment 12

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: mohs_micrographic_surgery 07/2004 11/2017 11/2018 11/2017 Description of Procedure or Service Mohs Micrographic

More information

Policy #: 127 Latest Review Date: June 2011

Policy #: 127 Latest Review Date: June 2011 Name of Policy: Mohs Micrographic Surgery Policy #: 127 Latest Review Date: June 2011 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates. Background/Definitions:

More information

Clinical Policy Title: Indications for Mohs micrographic surgery (MMS)

Clinical Policy Title: Indications for Mohs micrographic surgery (MMS) Clinical Policy Title: Indications for Mohs micrographic surgery (MMS) Clinical Policy Number: 01.03.01 Effective Date: March 1, 2014 Initial Review Date: September 18, 2013 Most Recent Review Date: October

More information

If Mohs surgery is the 'gold standard for non-melanoma skin cancer treatment', why doesn't everyone have it? Antonio Ji Xu University of Oxford

If Mohs surgery is the 'gold standard for non-melanoma skin cancer treatment', why doesn't everyone have it? Antonio Ji Xu University of Oxford If Mohs surgery is the 'gold standard for non-melanoma skin cancer treatment', why doesn't everyone have it? Antonio Ji Xu University of Oxford British Society for Dermatological Surgery Medical Student

More information

British Society for Dermatological Surgery Undergraduate Essay Prize "There is no need to treat any skin cancer with Mohs surgery - discuss"

British Society for Dermatological Surgery Undergraduate Essay Prize There is no need to treat any skin cancer with Mohs surgery - discuss British Society for Dermatological Surgery Undergraduate Essay Prize 2015 "There is no need to treat any skin cancer with Mohs surgery - discuss" Monty Lyman The University of Birmingham 1 The late 20

More information

Clinical Policy Title: Cardiac rehabilitation

Clinical Policy Title: Cardiac rehabilitation Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review

More information

Clinical Policy Title: Zoster (shingles) vaccine

Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:

More information

ALASKA ARIZONA IDAHO MONTANA NORTH DAKOTA OREGON SOUTH DAKOTA UTAH WASHINGTON WYOMING

ALASKA ARIZONA IDAHO MONTANA NORTH DAKOTA OREGON SOUTH DAKOTA UTAH WASHINGTON WYOMING The following policy (L35704) has been archived by Alpha II. Many policies are part of a larger jurisdiction, than is indicated by the policy. This policy covers the following states: ALASKA ARIZONA IDAHO

More information

Better health with the best cosmetic result, no one can ask more from a surgical

Better health with the best cosmetic result, no one can ask more from a surgical Better health with the best cosmetic result, no one can ask more from a surgical procedure in the 21st century. (1) This phrase was used in the journal of Cutaneous and Aesthetics surgery in 2012 to describe

More information

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW MOHS MICROGRAPHIC SURGERY: AN OVERVIEW SKIN CANCER: Skin cancer is far and away the most common malignant tumor found in humans. The most frequent types of skin cancer are basal cell carcinoma, squamous

More information

Clinical Policy Title: Strep testing

Clinical Policy Title: Strep testing Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:

More information

MOHS SURGERY FOR NMSC IS IT REALLY NESESSARY???

MOHS SURGERY FOR NMSC IS IT REALLY NESESSARY??? MOHS SURGERY FOR NMSC IS IT REALLY NESESSARY??? Mariana Zamir, MD MOHS and Dermatosurgery Unit Department of Dermatology Hadassah - Hebrew University Medical Center Jerusalem Why talking about Mohs surgery???

More information

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent

More information

Clinical Policy Title: Genicular nerve block

Clinical Policy Title: Genicular nerve block Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review

More information

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based

More information

Living Beyond Cancer Skin Cancer Detection and Prevention

Living Beyond Cancer Skin Cancer Detection and Prevention Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common

More information

For additional information on meeting the criteria for Mohs, see Appendix 2.

For additional information on meeting the criteria for Mohs, see Appendix 2. Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs

More information

PATIENT INFORMATION. Mohs Micrographic Surgery. In the Treatment of Skin Cancer

PATIENT INFORMATION. Mohs Micrographic Surgery. In the Treatment of Skin Cancer PATIENT INFORMATION Mohs Micrographic Surgery In the Treatment of Skin Cancer What is Mohs Micrographic Surgery? Mohs micrographic surgery is a specialized, highly effective technique for the removal

More information

Clinical Policy Title: Abdominal aortic aneurysm screening

Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next

More information

Frequently Asked Questions

Frequently Asked Questions Ida Orengo, M.D. Mohsin Mir, M.D. Department of Dermatology 1977 Butler Boulevard, Suite E6.200 Houston, TX 77030 (713) 798-6925 / (713) 798-6624 telephone (713) 798-5535 fax Frequently Asked Questions

More information

Clinical Policy Title: Abdominal aortic aneurysm screening

Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next

More information

Clinical Policy Title: Abdominal aortic aneurysm screening

Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next

More information

Modular Program Report

Modular Program Report Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also

More information

Clinical Policy Title: Dermabrasion and chemical peels

Clinical Policy Title: Dermabrasion and chemical peels Clinical Policy Title: Dermabrasion and chemical peels Clinical Policy Number: 16.02.09 Effective Date: August 1, 2017 Initial Review Date: July 20, 2017 Most Recent Review Date: August 17, 2017 Next Review

More information

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Sarah Patton, PA-C, MSHS Skin Surgery Center www.skinsurgerycenter.com Seattle/Bellevue, WA Skin cancer Skin cancer is by far the most

More information

MOHS MICROGRAPHIC SURGERY

MOHS MICROGRAPHIC SURGERY MOHS MICROGRAPHIC SURGERY What are the aims of this leaflet? This leaflet has been written to help you understand more about Mohs micrographic surgery. It tells you what it is, what is involved and what

More information

Mohs. Micrographic Surgery. For Treating Skin Cancer

Mohs. Micrographic Surgery. For Treating Skin Cancer Mohs Micrographic Surgery For Treating Skin Cancer Skin Cancer Basics Skin cancer is common. Over the past three decades, more people have had skin cancer than all other cancers combined. Each year in

More information

5/20/2015. Mohs Surgery BCCA High risk anatomic locations. Mohs Surgery High risk anatomic locations. Mohs Surgery Histologically Aggressive BCCA

5/20/2015. Mohs Surgery BCCA High risk anatomic locations. Mohs Surgery High risk anatomic locations. Mohs Surgery Histologically Aggressive BCCA Mohs Surgery BCCA High risk anatomic locations High risk areas H zone nasal ala, nasal septum, nasal ala groove, periorbital region, periauricual region, region around and in ear canal, ear pinna and scalp

More information

Clinical Policy Title: Vacuum assisted closure in surgical wounds

Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Number: 17.03.00 Effective Date: September 1, 2015 Initial Review Date: June 16, 2013 Most Recent Review Date: August 17,

More information

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab

Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent

More information

Clinical Policy Title: Breast cancer index genetic testing

Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016

More information

Mohs surgery for the nail unit

Mohs surgery for the nail unit Mohs surgery for the nail unit olivier.cogrel@chu-bordeaux.fr Dermatologic surgery, Mohs surgery and lasers unit CHU Bordeaux, France Squamous cell carcinoma +++ Acral lentiginous melanoma Lichte et al.

More information

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment

More information

FDA INDICATIONS Mohs surgery is a procedure and is not regulated by the Food and Drug Administration.

FDA INDICATIONS Mohs surgery is a procedure and is not regulated by the Food and Drug Administration. Subject: Micrographic (Mohs) Surgery for Cancerous and Noncancerous Lesions Guidance Number: MCG-135 Revision Date(s): Original Effective Date: 6/26/13 Medical Coverage Guidance Approval Date: 6/26/13

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals

More information

STUDY. Mohs Micrographic Surgery and Surgical Excision for Nonmelanoma Skin Cancer Treatment in the Medicare Population

STUDY. Mohs Micrographic Surgery and Surgical Excision for Nonmelanoma Skin Cancer Treatment in the Medicare Population STUDY Mohs Micrographic Surgery and Surgical Excision for Nonmelanoma Skin Cancer Treatment in the Medicare Population Kate V. Viola, MD, MHS; Mamta B. Jhaveri, MD, MS; Pamela R. Soulos, MPH; Ryan B. Turner,

More information

Important Information about Mohs Micrographic Surgery

Important Information about Mohs Micrographic Surgery Important Information about Mohs Micrographic Surgery Highly effective skin cancer treatment What is Mohs micrographic surgery? Mohs micrographic surgery is a highly effective technique for removing skin

More information

Periocular skin cancer

Periocular skin cancer Periocular skin cancer Information for patients Skin cancer involving the skin of the eyelid or around the eye is called a periocular skin cancer. Eyelid skin cancers occur most often on the lower eyelid,

More information

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma

More information

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate

More information

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D. Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma

More information

Clinical Policy Title: Ketamine for treatment-resistant depression

Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our

More information

Related Policies None

Related Policies None Medical Policy MP 8.01.62 BCBSA Ref. Policy: 8.01.62 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

Alcohol should be avoided for 3 days prior to surgery and 2 days after the procedure.

Alcohol should be avoided for 3 days prior to surgery and 2 days after the procedure. Mohs Surgery Information Packet Be sure to bring the following to your appointment: Insurance Card Insurance Referral ( If required by your insurance) Name and address of your primary care provider as

More information

Knowledge-Powered Medicine

Knowledge-Powered Medicine mohs surgery A patient guide to specialized treatment for skin cancer Knowledge-Powered Medicine upgdocs.org/dermatology upgdocs.org/dermatology A patient guide Preparing for Mohs Surgery > What is Mohs

More information

ENCR RECOMMENDATIONS

ENCR RECOMMENDATIONS E N C R EUROPEAN NETWORK OF CANCER REGISTRIES (ENCR) ENCR RECOMMENDATIONS Non-Melanoma Skin Cancers Members of the Working Group: Dr T. Davies, East Anglian Cancer Registry, Cambridge, UK Mrs M. Page,

More information

Outcomes in Oncology

Outcomes in Oncology Outcomes in Oncology Ochsner Cancer Institute s Report to Physicians July 2014 ochsner.org/cancer Treatment Advances in Skin Cancer Rodney J. Landreneau, M.D. Medical Director, Ochsner Cancer Institute

More information

UWMC Roosevelt Clinic Rotation Goals 2011 Procedural Dermatology Fellowship Program 1

UWMC Roosevelt Clinic Rotation Goals 2011 Procedural Dermatology Fellowship Program 1 Procedural Dermatology Fellowship Objectives University of Washington Medical Center-Roosevelt Rotation The primary goal of the University of Washington rotation of the Procedural Dermatology fellowship

More information

Moh's Surgery Information Packet

Moh's Surgery Information Packet Moh's Surgery Information Packet BE SURE TO BRING THE FOLLOWING TO YOUR APPOINTMENT Insurance card Insurance referral (if required by your insurance) Name and address of your primary care provider as well

More information

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018 A D E E P E R L O O K When detected early, most cases of local cutaneous squamous cell carcinoma are easily treated and usually cured. But when they become more advanced, this second most common form of

More information

MOHS MICROGRAPHIC SURGERY

MOHS MICROGRAPHIC SURGERY MOHS MICROGRAPHIC SURGERY The Treatment of Skin Cancer What is Mohs Micrographic Surgery? Mohs Micrographic surgery is a specialized, highly effective technique used to treat skin cancer. The goal of Mohs

More information

Patient Guide. The precise answer for tackling skin cancer. Brachytherapy: Because life is for living

Patient Guide. The precise answer for tackling skin cancer. Brachytherapy: Because life is for living Patient Guide Brachytherapy: The precise answer for tackling skin cancer Because life is for living Overview of skin cancer Skin cancer is the most common cancer worldwide. In fact more people are diagnosed

More information

MOHS MICROGRAPHIC SURGERY

MOHS MICROGRAPHIC SURGERY MOHS MICROGRAPHIC SKIN CANCER Skin cancer is by far the most common malignant tumor in humans. The most common types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and melanoma. Both

More information

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma

More information

Electronic Brachytherapy for Nonmelanoma Skin Cancer

Electronic Brachytherapy for Nonmelanoma Skin Cancer Electronic Brachytherapy for Nonmelanoma Skin Cancer Policy Number: 8.01.62 Last Review: 1/2018 Origination: 01/2016 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Radiation (ebt/hdr) for Non-Melanoma Skin Cancers (NMSCC) in the Dermatologist s Office: A Radiation Oncologist s (Generally Positive) Perspective

Radiation (ebt/hdr) for Non-Melanoma Skin Cancers (NMSCC) in the Dermatologist s Office: A Radiation Oncologist s (Generally Positive) Perspective Radiation (ebt/hdr) for Non-Melanoma Skin Cancers (NMSCC) in the Dermatologist s Office: A Radiation Oncologist s (Generally Positive) Perspective Mohammad K Khan MD Ph.D FACRO Associate Professor Director,

More information

Mohs surgery. Information for patients Dermatology

Mohs surgery. Information for patients Dermatology Mohs surgery Information for patients Dermatology Why have I been given this leaflet? You have been given this leaflet because you are going to have a procedure known as Mohs surgery. This leaflet explains

More information

Interesting Case Series. Aggressive Tumor of the Midface

Interesting Case Series. Aggressive Tumor of the Midface Interesting Case Series Aggressive Tumor of the Midface Adrian Frunza, MD, Dragos Slavescu, MD, and Ioan Lascar, MD, PhD Bucharest Emergency Clinical Hospital, Bucharest University School of Medicine,

More information

Texas Prior Authorization Program Clinical Criteria

Texas Prior Authorization Program Clinical Criteria Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

General information about skin cancer

General information about skin cancer Skin Cancer General information about skin cancer Key points Skin cancer is a disease in which malignant (cancer) cells form in the tissues of the skin. There are different types of cancer that start in

More information

Electronic Brachytherapy for Nonmelanoma Skin Cancer

Electronic Brachytherapy for Nonmelanoma Skin Cancer Electronic Brachytherapy for Nonmelanoma Skin Cancer Policy Number: 8.01.62 Last Review: 1/2019 Origination: 01/2016 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions

Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Original Effective Date: MM.02.016 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST

More information

MING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1)

MING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1) Curettage prior to Mohs Micrographic Surgery for Previously Biopsied Nonmelanoma Skin Cancers: What Are We Curetting? Retrospective, Prospective, and Comparative Study MING H. JIH, MD,PHD, PAUL M. FRIEDMAN,

More information

MOHS SURGERY -The Myth and the Truth-

MOHS SURGERY -The Myth and the Truth- Review MOHS SURGERY -The Myth and the Truth- Tsu-Yi Chuang Since Dr. Frederic E. Mohs invented the Mohs Surgery in 1936, Mohs Micrographic Surgery (MMS) has been utilized by many to remove ill-defined

More information

The Role of Mohs Micrographic Surgery in Skin Cancer Treatment

The Role of Mohs Micrographic Surgery in Skin Cancer Treatment Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/the-role-of-mohs-micrographic-surgery-in-skincancer-treatment/3643/

More information

Coding Companion for Orthopaedics Lower: Hips & Below. A comprehensive illustrated guide to coding and reimbursement

Coding Companion for Orthopaedics Lower: Hips & Below. A comprehensive illustrated guide to coding and reimbursement Coding Companion for Orthopaedics Lower: Hips & Below comprehensive illustrated guide to coding and reimbursement 2015 Contents Getting Started with Coding Companion...i Skin...1 Nails...12 Repair...21

More information

Clinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150

Clinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150 Clinical Policy: Reference Number: CP.MP.HN150 Effective Date: 6/04 Last Review Date: 8/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent

More information

Clinical Policy Title: Computerized gait analysis

Clinical Policy Title: Computerized gait analysis Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: May 1, 2018 Next Review Date:

More information

Cryosurgical Ablation of Breast Fibroadenomas

Cryosurgical Ablation of Breast Fibroadenomas Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee

I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something

More information

A Multi Site Prospective Study of the Adverse Events and Complications Associated with Mohs Micrographic Surgery. Nicole Y. Lee

A Multi Site Prospective Study of the Adverse Events and Complications Associated with Mohs Micrographic Surgery. Nicole Y. Lee A Multi Site Prospective Study of the Adverse Events and Complications Associated with Mohs Micrographic Surgery By Nicole Y. Lee A Master s Paper submitted to the faculty of the University of North Carolina

More information

Dermatology Procedure Coding

Dermatology Procedure Coding Dermatology Procedure Coding Anatomy Two layers that make up human skin Epidermis most superficial layer Composed of four to five layers called stratum Anyone remember the mnemonic? Thickness varies based

More information

Section 1: Personal information

Section 1: Personal information A survey on the use of ultrasound examination of the regional lymph nodes in the follow up of patients with high-risk cutaneous squamous cells carcinomas (SCCs). Note: In the definition of cutaneous squamous

More information

Summary. Electronic brachytherapy for the treatment of nonmelanoma skin cancer is considered investigational.

Summary. Electronic brachytherapy for the treatment of nonmelanoma skin cancer is considered investigational. Last Review Status/Date: September 2016 Page: 1 of 7 Summary Electronic brachytherapy is a form of radiotherapy that is designed to deliver high-dose rate (HDR) brachytherapy for the treatment of nonmelanoma

More information

Clinical Policy Title: Ear tubes (tympanostomy)

Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 1135 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: August 1, 2018 Next Review

More information

Using the Mohs Technique for Thin Melanomas

Using the Mohs Technique for Thin Melanomas Dermatology Associates Mohs Micrographic Surgery 2300 W Stone Drive Kingsport TN 37660 Telephone 423-246-4961 1-800-445-7274 (VA Toll Free) Fax 423-245-1200 Using the Mohs Technique for Thin Melanomas

More information

Clinical Policy Title: Epidermal nerve fiber density testing

Clinical Policy Title: Epidermal nerve fiber density testing Clinical Policy Title: Epidermal nerve fiber density testing Clinical Policy Number: CCP.1263 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 2, 2018

More information

Evidence for Mohs surgery

Evidence for Mohs surgery Evidence for Mohs surgery Simone van der Geer Dermatologist, Mohs surgeon Secretary of the ESMS Excision Mohs 3-5 mm clinical margin 0,1% margin control (Abide, The meaning of surgical margins. Plast Reconstr

More information

Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary

Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication

More information

Skin disorders. Basal cell carcinoma December 2009 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig ...

Skin disorders. Basal cell carcinoma December 2009 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig ... December 29 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig.................................................. ABSTRACT INTRODUCTION: (BCC) is the most common form of skin cancer, predominantly affecting

More information

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.

More information

Summary of Package Insert 1 for PuraPly Wound Matrix

Summary of Package Insert 1 for PuraPly Wound Matrix Summary of Package Insert 1 for PuraPly Wound Matrix For NGS Indications Indicated for the management of wounds including: Partial and full-thickness wounds Venous ulcers Diabetic ulcers Drainage wounds

More information

BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES

BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES Recommendations of the British Society for Dermatological Surgery and British Association

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.

More information

SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016

SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016 Attachment A SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016 Deleted items 31200-31215, 31230-31240 31255-31335 Colour Coding for new / updated items: MUCOSAL BIOPSY AND

More information

Basic Standards for Fellowship Training in Mohs Micrographic Surgery

Basic Standards for Fellowship Training in Mohs Micrographic Surgery Basic Standards for Fellowship Training in Mohs Micrographic Surgery American Osteopathic Association and American Osteopathic College of Dermatologists September, 1992 BOT/93 BOT 7/2011, Eff. 7/2012 Basic

More information

Clinical Policy Title: Computerized gait analysis

Clinical Policy Title: Computerized gait analysis Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: June 22, 2017 Next Review Date:

More information

Coding Companion for Podiatry. A comprehensive illustrated guide to coding and reimbursement

Coding Companion for Podiatry. A comprehensive illustrated guide to coding and reimbursement Coding Companion for Podiatry comprehensive illustrated guide to coding and reimbursement 2016 Contents Contents Foot and Toes 28043-28045 [28039, 28041] 28043 28039 28045 28041 Excision, tumor, soft tissue

More information

New and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ

New and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ New and Emerging Therapies: Non-Melanoma Skin Cancers David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ Disclosure Research Grant form Sensus Superficial Radiation Therapy (SRT) Modern

More information

ICD 10 Codes. L82.1 Seborrheic Keratosis L82.0 Irritated Seborrheic Keratosis

ICD 10 Codes. L82.1 Seborrheic Keratosis L82.0 Irritated Seborrheic Keratosis Leon H. Kircik M.D. Clinical Associate Professor of Dermatology Indiana University School of Medicine Mount Sinai Medical Center, New York, NY Physicians Skin Care, PLLC Louisville, KY 1 ICD 10 Codes L82.1

More information

Clinical Policy Title: Ear tubes (tympanostomy)

Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 11.03.05 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next

More information